Press Releases

Intercytex expands Executive Management team

Cambridge, UK, 6 September 2005 - Intercytex, the cell therapy company developing products for the advanced woundcare and aesthetic medicine markets, today announces the appointment of John St Clair Roberts MRCS, LRCP, FFPM, as Vice President Medical Affairs.

Dr St Clair Roberts has over 20 years of experience in the clinical development of vaccines and biological products. Previously he held the position of Medical Director at a number of leading biotechnology companies including Microscience plc, Xenova Group plc, Cantab Pharmaceuticals plc and Merieux UK.

He graduated in medicine from the Royal College of Surgeons in Ireland and, prior to his career in industry, he practised hospital medicine for a number of years in the National Health Service (UK). He has contributed to numerous publications, presentations, technical committees and lectures and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians and the Royal Society of Medicine.

“I am delighted to welcome John to Intercytex,” said Nick Higgins, Intercytex’ Chief Executive Officer. “He brings a wealth of clinical, regulatory and medical expertise to the Company, which will be invaluable to Intercytex at this stage of its corporate and product development.”

In January 2005, Intercytex appointed Nick Higgins, formerly Chief Business Officer at Acambis plc, as Chief Executive Officer. In August 2005, Alan Suggett (formerly Group Director of Technology, Smith & Nephew plc) and John Aston (Chief Financial Officer, Cambridge Antibody Technology plc) were appointed Non-Executive Directors to its Board.

Enquiries:

Intercytex
Nick Higgins, Chief Executive Officer: +44 (0) 161 904 4500

Financial Dynamics
David Yates/Davina Langdale: +44 (0) 207 831 3113

About Intercytex:

Intercytex is an emerging healthcare company developing cell therapy products for the woundcare and aesthetic medicine markets. It is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex has two products currently in clinical development, ICX-PRO and ICX-TRC. ICX-PRO is designed to actively stimulate repair in chronic wounds and is currently in Phase III trials. ICX-TRC is a hair regeneration product in Phase I trials. A third product, ICX-SKN, is in preclinical trials being developed as a true skin replacement to overcome the need for skin graft procedures. All Intercytex’ products are derived from unmodified, normal human cells.

Intercytex commenced operations in 2000 and has raised over £31 million in four private equity financing rounds. The Company has around 60 employees and is headquartered in Cambridge, UK with GMP clinical production facilities and research located in Manchester, UK and additional research laboratories in Boston, MA.

For further details about Intercytex, please visit www.intercytex.com